NASDAQ:SLDB

Solid Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy SLDB

*Your capital is at risk

$8.30

-0.0300 (-0.360%)

At Close: Jun 22, 2026

Solid Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 15.18. In total, the insiders bought 14.11M and sold 397.47K SLDB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	15.18
● Buy	14.11M shares
● Sell	397.47K shares
78% Buy Activity Weak Positive Correlation
Sell Signal Low Confidence Feb 04, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Nagendran Sukumar Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Smith Ian F Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Ganot Ilan Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Perceptive Advisors Llc	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Kahn Clare Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Freed Martin I Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Keresty Georgia Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Sullivan Lynne Marie Director	Director	77 500 Value: $512.3K
Jun 10, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Stone Adam Leo Director	Director	77 500 Value: $512.3K
Apr 02, 2026 Buy	Restricted Stock Units M-Exempt	Smith Ian F Director	Director	3 441 Value: $25.8K
Apr 02, 2026 Buy	Common Stock M-Exempt	Smith Ian F Director	Director	3 441 Value: $25.8K
Mar 09, 2026 Buy	Pre-Funded Warrant (right to buy) A-Award	Perceptive Advisors Llc	Director	8 912 655 Value: $9K
Feb 18, 2026 Sell	Common Stock S-Sale	Brooks Gabriel Chief Medical Officer	Officer	0 Value: $0
Feb 18, 2026 Sell	Common Stock S-Sale	Howton David T Chief Operating Officer	C-Suite Officer	7 469 Value: $43.5K
Feb 18, 2026 Sell	Common Stock S-Sale	Herzich Paul Chief Technology Officer	Officer	3 616 Value: $21.1K
Feb 18, 2026 Sell	Common Stock S-Sale	Ganot Ilan Director	Director	2 658 Value: $15.5K
Feb 18, 2026 Sell	Common Stock S-Sale	Hanrahan Jessie Chief Regulatory Officer	Officer	4 134 Value: $24.1K
Feb 18, 2026 Sell	Common Stock S-Sale	Cumbo Alexander President And CEO	CEO / President	16 644 Value: $96.9K
Feb 18, 2026 Sell	Common Stock S-Sale	Tan Kevin CFO & Treasurer	C-Suite Officer	5 404 Value: $31.5K
Feb 13, 2026 Buy	Restricted Stock Units M-Exempt	Brooks Gabriel Chief Medical Officer	Officer	10 937 Value: $67.7K
Feb 13, 2026 Buy	Common Stock M-Exempt	Howton David T Chief Operating Officer	C-Suite Officer	14 687 Value: $90.9K
Feb 13, 2026 Buy	Restricted Stock Units M-Exempt	Herzich Paul Chief Technology Officer	Officer	7 187 Value: $44.5K
Feb 13, 2026 Buy	Common Stock M-Exempt	Herzich Paul Chief Technology Officer	Officer	7 187 Value: $44.5K
Feb 13, 2026 Buy	Restricted Stock Units M-Exempt	Ganot Ilan Director	Director	4 861 Value: $30.1K
Feb 13, 2026 Buy	Common Stock M-Exempt	Ganot Ilan Director	Director	4 861 Value: $30.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SOLID BIOSCIENCES INC.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...

Read Full Profile Here